Suboxone.com - Here to Help®

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "View PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

You are leaving Suboxone.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals. You are solely responsible for your interactions with such websites.

Links are provided as a public service and for informational purposes only.

You are leaving Suboxone.com and are being redirected to HereToHelpProgram.com, the website that contains the information you requested. HereToHelpProgram.com and Suboxone.com are owned and operated by Reckitt Benckiser Pharmaceuticals Inc.

As always, your information will not be sold or shared with anyone. See our privacy policy for more information.

IMPORTANT INFORMATION:

On December 8, 2006, Federal legislation was passed allowing physicians to treat up to 100 opioid-dependent patients with Suboxone at any given time—a significant increase from the previous limit of 30 patients.

There may be doctors in your area participating in a study to measure opioid dependence treatment outcomes. Patients who meet the eligibility requirements to participate in this study can receive up to $225 in compensation to complete surveys about their treatment.

NOTE: This study is only open to patients not currently under the care of a physician for opioid dependence and are seeking a treatment provider.

Please call 1-866-455-8876 between 9:00 AM to 7:30 PM EST to get more information.

Seeking Information for myself or loved one

Here to Help™ provides support throughout treatment. Whether you're seeking treatment information or you're already in treatment, we can provide resources that can help you make treatment a success.

HereToHelpProgram.com respects your privacy.
Read our Privacy Policy for more information.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Prescribing Information -- Site Map

Support That Helps Patients Stay In Treatment

Learn how patients can benefit from this free support system

Become a Here to Help Provider

Learn how becoming a provider can benefit you and your practice

See why your peers prefer SUBOXONE and value Here to Help for their practice

The Here to Help^® Program

Here to Help is a fully funded comprehensive patient support program with exclusive access for opioid-dependent patients being treated with SUBOXONE. Here to Help provides personalized support at every phase of treatment and recovery. In an evaluation of the program, it was found to increase patient adherence to medication and increase the likelihood of patient success.¹

Advantages of Here to Help to Your Practice

Assists in retaining patients in treatment and helps support longer-term success by keeping patients motivated and committed to their treatment goals
Emphasizes the importance of counseling and, if requested, helps connect patients to a network of counselors
Allows for more quality time you spend with patients by helping them get general questions answered outside of the office
Assists patients with visit reminders to reduce missed appointments
Helps patients be better prepared for their appointments, reducing time spent by your office staff

Enroll as a Here to Help provider and be added to the physician network

Patient Benefits of Here to Help

A locator service to help patients find local Here to Help enrolled providers
Patient support from a live personal Care Coach—a trained professional who is just a phone call away
Care Coaches are available for patients to call anytime between 8:00 am and 11:00 pm Monday through Friday Eastern Time (ET), and 8:00 am to 8:00 pm ET Saturday for additional support
Patient access to a comprehensive, educational website at HereToHelpProgram.com
Weekly e-mail support through the first 26 weeks of patients' treatment
Access to live and online counseling resources

Have patients call 866-973-HERE (4373) or visit HereToHelpProgram.com to enroll today.

Reference

1.	Data on file, Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA.

Home -- About SUBOXONE -- Here to Help -- Treatment -- Certification -- Pharmacists -- Counselors -- Nurses -- Resources

SUBOXONE^®, SUBUTEX^®, and Here to Help^® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.

Important Safety Information

SUBOXONE^® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.

It is extremely dangerous to self-administer non-prescribed benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE.

SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists.

Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine.

Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine.

There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy.

Caution should be exercised when driving cars or operating machinery.

Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately.

The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and sweating (14%, placebo 10%). Please see full Prescribing Information for a complete list.

To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information